FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

In this article

The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk

, a landmark decision that health experts say could open up treatment access to more patients.

Novo Nordisk said it expects to launch the pill in early 2026. The Danish drugmaker said the starting dose of 1.5 milligrams will be available starting in early January in pharmacies and via select telehealth providers for $149 per month.

Novo Nordisk did not say how much higher doses of the drug would cost, but said additional information on coverage and savings options for eligible patients will be available at that time as well.